Bavarian Nordic A/S (BVNRY)
11.04
+0.17
(+1.56%)
USD |
OTCM |
Aug 24, 16:00
Bavarian Nordic Enterprise Value : 2.176B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.176B |
| August 21, 2026 | 2.138B |
| August 20, 2026 | 1.928B |
| August 19, 2026 | 1.934B |
| August 18, 2026 | 1.877B |
| August 17, 2026 | 1.856B |
| August 14, 2026 | 1.834B |
| August 13, 2026 | 1.783B |
| August 12, 2026 | 1.766B |
| August 11, 2026 | 1.717B |
| August 10, 2026 | 1.717B |
| August 07, 2026 | 1.731B |
| August 06, 2026 | 1.751B |
| August 05, 2026 | 1.751B |
| August 04, 2026 | 1.751B |
| August 03, 2026 | 1.754B |
| July 31, 2026 | 1.738B |
| July 30, 2026 | 1.722B |
| July 29, 2026 | 1.710B |
| July 28, 2026 | 1.710B |
| July 27, 2026 | 1.668B |
| July 24, 2026 | 1.656B |
| July 23, 2026 | 1.690B |
| July 22, 2026 | 1.756B |
| July 21, 2026 | 1.756B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.769B |
| July 17, 2026 | 1.791B |
| July 16, 2026 | 1.821B |
| July 15, 2026 | 1.786B |
| July 14, 2026 | 1.774B |
| July 13, 2026 | 1.742B |
| July 10, 2026 | 1.779B |
| July 09, 2026 | 1.804B |
| July 08, 2026 | 1.829B |
| July 07, 2026 | 1.881B |
| July 06, 2026 | 1.881B |
| July 02, 2026 | 1.848B |
| July 01, 2026 | 1.790B |
| June 30, 2026 | 1.783B |
| June 29, 2026 | 1.806B |
| June 26, 2026 | 1.763B |
| June 25, 2026 | 1.752B |
| June 24, 2026 | 1.738B |
| June 23, 2026 | 1.744B |
| June 22, 2026 | 1.732B |
| June 18, 2026 | 1.793B |
| June 17, 2026 | 1.795B |
| June 16, 2026 | 1.813B |
| June 15, 2026 | 1.864B |
| June 12, 2026 | 1.854B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Evaxion AS | 21.46M |
| Genmab A/S | 23.48B |
| Ascendis Pharma A/S | 16.13B |
| Zealand Pharma A/S | 1.219B |
| Agenus, Inc. | 591.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 113.83M |
| Revenue (Quarterly) | 315.94M |
| Total Expenses (Quarterly) | 202.11M |
| EPS Diluted (Quarterly) | 0.4995 |
| Gross Profit Margin (Quarterly) | 60.45% |
| Profit Margin (Quarterly) | 36.03% |
| Earnings Yield | 9.43% |
| Operating Earnings Yield | 6.22% |
| Normalized Earnings Yield | 9.102 |